Tesamorelin

Overview

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) marketed under the brand name Egrifta. It is approved by the U.S. Food and Drug Administration for a specific indication: the reduction of excess visceral abdominal fat in adults living with HIV who have lipodystrophy, a condition in which fat redistributes abnormally, often as a consequence of antiretroviral therapy.

Unlike injected growth hormone itself, tesamorelin does not directly supply the body with growth hormone. Instead, it stimulates the pituitary gland to produce and release the body's own growth hormone in a more physiological pattern. This distinction is central to how it is positioned clinically and to its regulatory standing.

It is important to frame tesamorelin accurately. It is an approved prescription medication for a narrow, well-defined population, not a general weight-loss drug or a cosmetic enhancement agent. Its evidence base, labeling, and safety monitoring are tied specifically to HIV-associated visceral adiposity, and use outside that context is not supported by its approval.

How it works

Tesamorelin mimics the action of endogenous GHRH, a hypothalamic peptide that signals the anterior pituitary gland. By binding GHRH receptors on pituitary cells, it prompts the pulsatile secretion of growth hormone. This released growth hormone then acts throughout the body and stimulates the liver to produce insulin-like growth factor 1, or IGF-1, which mediates many of growth hormone's downstream effects.

Because it works upstream by amplifying a natural signaling pathway, tesamorelin tends to preserve more of the body's normal feedback regulation than direct growth hormone administration. The structural modification of the GHRH sequence improves stability against enzymatic breakdown, giving the molecule a longer functional window than native GHRH.

The visceral fat reduction seen with tesamorelin is thought to reflect growth hormone's known lipolytic activity, meaning its tendency to promote the breakdown of stored fat, particularly in the abdominal compartment. Rising IGF-1 levels serve as a measurable marker of biological activity and are monitored during treatment.

Clinical evidence

Tesamorelin's approval rests on randomized, placebo-controlled phase 3 trials conducted in adults with HIV-associated lipodystrophy. These studies measured visceral adipose tissue using imaging and demonstrated meaningful reductions in abdominal visceral fat among treated participants compared with placebo, with partial regain after discontinuation.

The trials also tracked IGF-1 levels, lipid parameters, and patient-reported outcomes related to body image. Reported benefits were specific to the visceral fat depot; the medication was not established as a treatment for subcutaneous fat, general obesity, or weight reduction in the broader population.

Subsequent research has explored tesamorelin in other contexts, including studies examining liver fat in HIV-associated fatty liver disease. While such investigational work exists, these areas remain outside the approved indication. The strongest and most established evidence remains confined to the original HIV lipodystrophy population, and clinicians interpret newer findings cautiously pending further confirmation.

Dosing & side effects

Tesamorelin is administered as a subcutaneous injection and is available only by prescription, with dosing determined by a qualified healthcare provider. This guide does not provide dosing figures, as the medication requires individualized medical supervision, periodic monitoring, and appropriate patient selection.

Commonly reported side effects include injection-site reactions, joint pain, muscle aches, swelling, and flu-like symptoms. Because the drug raises growth hormone and IGF-1 activity, it can affect glucose metabolism, and clinicians typically monitor blood sugar, particularly in people with or at risk of diabetes. Fluid retention and carpal tunnel-type symptoms have also been described.

Tesamorelin carries contraindications and precautions, including in pregnancy and in people with certain active malignancies, reflecting theoretical concerns about growth-promoting signaling. Anyone considering it should have a thorough discussion with a prescriber about benefits, risks, and monitoring.

Legal status

Tesamorelin is a prescription medication approved by the FDA for HIV-associated lipodystrophy and is legally available in the United States through that pathway under the brand Egrifta. Its regulatory status in other countries varies, and availability depends on local health authority decisions.

Because it is approved only for a specific indication, use for cosmetic fat loss, athletic enhancement, or general anti-aging purposes falls outside its labeling. Such off-label or non-prescription use is not supported by its approval and may involve unregulated sources.

In the context of competitive sport, GHRH analogs that stimulate growth hormone secretion fall within the category of prohibited substances under anti-doping frameworks. Athletes subject to testing should assume that tesamorelin is not permitted and should consult the relevant anti-doping authority before any use.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. Peer-reviewed study
2. Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. Peer-reviewed study
3. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024. Peer-reviewed study
4. Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011. Peer-reviewed study
5. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. Peer-reviewed study
6. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012. Peer-reviewed study